Search results
Results from the WOW.Com Content Network
Rituximab, sold under the brand name Rituxan among others, is a monoclonal antibody medication used to treat certain autoimmune diseases and types of cancer. [18] It is used for non-Hodgkin lymphoma, chronic lymphocytic leukemia (in children and adults, but not recommended in elderly patients), rheumatoid arthritis, granulomatosis with polyangiitis, idiopathic thrombocytopenic purpura ...
Rituximab: MabThera, Rituxan: mab: chimeric: CD20: Y [109] lymphomas, leukemias, some autoimmune disorders Rivabazumab pegol [12] mab: humanized: Pseudomonas aeruginosa type III secretion system: Robatumumab: mab: human: IGF-1 receptor (CD221) cancer Rmab: RabiShield: human: rabies virus G glycoprotein: Y: post-exposure prophylaxis of rabies ...
rituximab: non-Hodgkin's lymphoma: Rituxan, MabThera 6750 7298 11 rivaroxaban: anticoagulant: Xarelto 6589 6234 12 aflibercept: Eylea 6551 5830 13 infliximab: Remicade 5908 7152 14 Pneumococcal conjugate vaccine: Prevnar 13 Prevenar 13 5802 5601 15 ustekinumab: Stelara 5156 4011 16 pregabalin: epilepsy: Lyrica 4970 5065
This regimen can also be combined with the monoclonal antibody rituximab if the lymphoma is of B cell origin; this combination is called R-CHOP. In 2002, a randomized controlled trial showed a higher complete response rate for R-CHOP vs CHOP in elderly patients with Diffuse Large-B-Cell Lymphoma (76% vs 63%). [ 4 ]
Cytokine reaction syndrome may also be induced by certain medications, such as the CD20 antibody rituximab and the CD19 CAR T cell tisagenlecleucel. The experimental drug TGN1412—also known as Theralizumab—caused extremely serious symptoms when given to six participants in a Phase I trial. [2]
McKesson Canada purchased Rexall in December 2016 for $3 billion from the Katz Group of Companies. [4] At the time, it was estimated that Rexall had an average annual revenue of approximately $2.0 to $2.5 billion. [5] Around this period, one of the major rival pharmacies in Canada was Shoppers Drug Mart. [6]
It is approved in the United States [8] and Canada, [9] and the European Union [5] to treat systemic lupus erythematosus and lupus nephritis. [ 10 ] The most common side effects include bacterial infections, such as bronchitis (infection in the lungs) and infection of the urinary tract (structures that produce or carry urine), diarrhea and ...
Tositumomab is a murine monoclonal antibody which targets the CD20 antigen produced in mammalian cell. [1] It was combined with iodine-131 to produce a radiopharmaceutical for unsealed source radiotherapy, Iodine-131 Tositumomab (branded as Bexxar), for the treatment of non-Hodgkins lymphoma. [1]